AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)
Diseases of the Cardiovascular System
What is the purpose of this trial?
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
- Ages45 years and older
- Trial withUniversity of Cincinnati
- Start Date06/16/2020
- End Date01/18/2022
- Last Updated07/15/2021
- Study HIC#2000024124